Your browser doesn't support javascript.
loading
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno, Lucas; Barone, Giuseppe; DuBois, Steven G; Molenaar, Jan; Fischer, Matthias; Schulte, Johannes; Eggert, Angelika; Schleiermacher, Gudrun; Speleman, Frank; Chesler, Louis; Geoerger, Birgit; Hogarty, Michael D; Irwin, Meredith S; Bird, Nick; Blanchard, Guy B; Buckland, Sean; Caron, Hubert; Davis, Susan; De Wilde, Bram; Deubzer, Hedwig E; Dolman, Emmy; Eilers, Martin; George, Rani E; George, Sally; Jaroslav, Sterba; Maris, John M; Marshall, Lynley; Merchant, Melinda; Mortimer, Peter; Owens, Cormac; Philpott, Anna; Poon, Evon; Shay, Jerry W; Tonelli, Roberto; Valteau-Couanet, Dominique; Vassal, Gilles; Park, Julie R; Pearson, Andrew D J.
  • Moreno L; Paediatric Haematology & Oncology Division, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: lucas.moreno@vhebron.net.
  • Barone G; Department of Paediatric Oncology, Great Ormond Street Hospital for Children, London, UK.
  • DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
  • Molenaar J; Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands.
  • Fischer M; Experimental Pediatric Oncology, University Children's Hospital, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Cologne, Germany.
  • Schulte J; Department of Pediatric Oncology & Hematology, Charité University Hospital, Berlin, Germany.
  • Eggert A; Department of Pediatric Oncology & Hematology, Charité University Hospital, Berlin, Germany; German Cancer Consortium (DKTK Berlin), Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany.
  • Schleiermacher G; SIREDO, Department of Paediatric, Adolescents and Young Adults Oncology and INSERM U830, Institut Curie, Paris, France.
  • Speleman F; Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Cancer Research Institute Ghent (CRIG), Belgium.
  • Chesler L; Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
  • Geoerger B; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, University Paris-Saclay & Inserm U1015, Villejuif, France.
  • Hogarty MD; Division of Oncology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, USA.
  • Irwin MS; Department of Paediatrics, Medical Biophysics and Laboratory Medicine & Pathobiology, The Hospital for Sick Kids, Toronto, Canada.
  • Bird N; Solving Kids' Cancer, UK and National Cancer Research Institute Children's Cancer & Leukaemia Clinical Studies Group, UK.
  • Blanchard GB; Neuroblastoma UK & Department of Physiology, Development & Neuroscience, University of Cambridge, UK.
  • Buckland S; Pfizer Ltd, Surrey, UK.
  • Caron H; Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Davis S; Cyclacel Limited, Dundee, UK.
  • De Wilde B; Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Cancer Research Institute Ghent (CRIG), Belgium.
  • Deubzer HE; Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Cologne, Germany.
  • Dolman E; Department of Translational Research, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Eilers M; Department of Biochemistry and Molecular Biology, University of Wuerzburg, Germany.
  • George RE; Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
  • George S; Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
  • Jaroslav S; Pediatric Oncology Department, University Hospital Brno, School of Medicine Masaryk University Brno, Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, ICRC Brno, St Anna University Hospital Brno, Czech Republic.
  • Maris JM; Division of Oncology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, USA.
  • Marshall L; Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
  • Merchant M; Astrazeneca, Early Clinical Projects, Oncology Translation Medicines Unit, Innovative Medicines Unit, Cambridge, UK.
  • Mortimer P; Astrazeneca, Early Clinical Projects, Oncology Translation Medicines Unit, Innovative Medicines Unit, Cambridge, UK.
  • Owens C; Department of Paediatric Haemaology/Oncology, Our Lady's Children's Hospital, Dublin, Ireland.
  • Philpott A; Department of Oncology, University of Cambridge, UK.
  • Poon E; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
  • Shay JW; Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Tonelli R; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
  • Valteau-Couanet D; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, University Paris-Saclay & Inserm U1015, Villejuif, France.
  • Vassal G; Department of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, France.
  • Park JR; Department of Pediatrics, University of Washington School of Medicine and Center for Clinical and Translational Research, Seattle Children's Hospital, USA.
  • Pearson ADJ; Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
Eur J Cancer ; 136: 52-68, 2020 09.
Article en En | MEDLINE | ID: mdl-32653773
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Desarrollo de Medicamentos / Neuroblastoma Límite: Child / Humans País como asunto: Europa Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Desarrollo de Medicamentos / Neuroblastoma Límite: Child / Humans País como asunto: Europa Idioma: En Año: 2020 Tipo del documento: Article